You are currently viewing a new version of our website. To view the old version click .

Vaccines, Volume 9, Issue 6

June 2021 - 147 articles

Cover Story: Polymer-based systems are considered as the next generation of nanovaccines. The properties, the characteristics, the added value, and the limitations of the polymer-based nanovaccines, as well as their development process by the pharmaceutical industry, are presented in this review. Polymer-based nanovaccines exhibit several advantages, such as strong cellular immune responses, adjuvant properties, increased secretion of cytokines, co-loading and prolonged circulation of antigens and increased levels of antibodies and antigen-specific antibodies. Additionally, different and needle-free routes of administration are available for the polymer-based nanovaccines. Considering the formulation diversity of polymer-based nanovaccines is a new horizon for vaccinology in the coming years. View this paper.
  • Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
  • You may sign up for email alerts to receive table of contents of newly released issues.
  • PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.

Articles (147)

  • Article
  • Open Access
54 Citations
4,973 Views
12 Pages

Safety of ChAdOx1 nCoV-19 Vaccine: Independent Evidence from Two EU States

  • Abanoub Riad,
  • Andrea Pokorná,
  • Mohamed Mekhemar,
  • Jonas Conrad,
  • Jitka Klugarová,
  • Michal Koščík,
  • Miloslav Klugar and
  • Sameh Attia

Recent reports of thrombosis following AstraZeneca COVID-19 vaccine in young females (<55 years-old) led to temporary suspension and urgent investigation by the European Medicines Agency (EMA) that concluded that vaccine benefits still outweigh it...

  • Article
  • Open Access
118 Citations
14,125 Views
8 Pages

Evaluation of Side Effects Associated with COVID-19 Vaccines in Saudi Arabia

  • Abdulaziz Alhazmi,
  • Edrous Alamer,
  • Dalia Daws,
  • Mashael Hakami,
  • Majid Darraj,
  • Siddig Abdelwahab,
  • Amani Maghfuri and
  • Abdullah Algaissi

Background: Pfizer-BioNTech and Oxford-AstraZeneca are recently introduced vaccines to combat COVID-19 pandemic. During clinical trials, mild to moderate side effects have been associated with these vaccines. Thus, we aimed to evaluate short-term pos...

  • Article
  • Open Access
44 Citations
7,298 Views
12 Pages

COVID-19 Vaccine Hesitancy in a Representative Education Sector Population in Qatar

  • Reem Al-Mulla,
  • Marawan Abu-Madi,
  • Qusai M. Talafha,
  • Reema F. Tayyem and
  • Atiyeh M. Abdallah

Even though vaccination programs have now started in earnest across the globe and in Qatar, vaccine hesitancy remains a barrier to effectively tackling the pandemic. Many factors influence willingness to take vaccines including safety, efficacy, and...

  • Article
  • Open Access
58 Citations
6,635 Views
11 Pages

Acceptance of COVID-19 Vaccine among the Healthcare Workers in the Eastern Cape, South Africa: A Cross Sectional Study

  • Oladele Vincent Adeniyi,
  • David Stead,
  • Mandisa Singata-Madliki,
  • Joanne Batting,
  • Matthew Wright,
  • Eloise Jelliman,
  • Shareef Abrahams and
  • Andrew Parrish

Background: This study assesses the perceptions and acceptance of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccination. It also examines its influencing factors among the healthcare workers (HCWs) in the Eastern Cape, South Africa...

  • Review
  • Open Access
61 Citations
8,801 Views
30 Pages

Cancer Vaccines: Promising Therapeutics or an Unattainable Dream

  • Howard Donninger,
  • Chi Li,
  • John W. Eaton and
  • Kavitha Yaddanapudi

The advent of cancer immunotherapy has revolutionized the field of cancer treatment and offers cancer patients new hope. Although this therapy has proved highly successful for some patients, its efficacy is not all encompassing and several cancer typ...

  • Article
  • Open Access
68 Citations
8,972 Views
13 Pages

In Silico Prediction of a Multitope Vaccine against Moraxella catarrhalis: Reverse Vaccinology and Immunoinformatics

  • Mohamed A. Soltan,
  • Nada Elbassiouny,
  • Helmy Gamal,
  • Eslam B. Elkaeed,
  • Refaat A. Eid,
  • Muhammad Alaa Eldeen and
  • Ahmed A. Al-Karmalawy

Moraxella catarrhalis (M. catarrhalis) is a Gram-negative bacterium that can cause serious respiratory tract infections and middle ear infections in children and adults. M. catarrhalis has demonstrated an increasing rate of antibiotic resistance in t...

  • Review
  • Open Access
21 Citations
6,533 Views
19 Pages

Immunization and Immunotherapy Approaches against Pseudomonas aeruginosa and Burkholderia cepacia Complex Infections

  • Sílvia A. Sousa,
  • António M. M. Seixas,
  • Joana M. M. Marques and
  • Jorge H. Leitão

Human infections caused by the opportunist pathogens Burkholderia cepacia complex and Pseudomonas aeruginosa are of particular concern due to their severity, their multiple antibiotic resistance, and the limited eradication efficiency of the current...

  • Article
  • Open Access
20 Citations
6,276 Views
7 Pages

First Dose of the BNT162b2 mRNA COVID-19 Vaccine Reduces Symptom Duration and Viral Clearance in Healthcare Workers

  • Luca Coppeta,
  • Ottavia Balbi,
  • Zaira Grattagliano,
  • Grazia Genga Mina,
  • Antonio Pietroiusti,
  • Andrea Magrini,
  • Matteo Bolcato and
  • Marco Trabucco Aurilio

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected more than one hundred million people since the beginning of the worldwide pandemic. In this study, data from a large hospital in central Italy was used to evaluate the impact o...

  • Article
  • Open Access
11 Citations
5,280 Views
10 Pages

Development of a Macrophage-Based ADCC Assay

  • Melissa B. Uccellini,
  • Sadaf Aslam,
  • Sean T. H. Liu,
  • Fahmida Alam and
  • Adolfo García-Sastre

Fc-dependent effector functions are an important determinant of the in vivo potency of therapeutic antibodies. Effector function is determined by the combination of FcRs bound by the antibody and the cell expressing the relevant FcRs, leading to anti...

of 15

Get Alerted

Add your email address to receive forthcoming issues of this journal.

XFacebookLinkedIn
Vaccines - ISSN 2076-393XCreative Common CC BY license